Pfizer (US)'s subsidiary in Saudi Arabia has formally opened a new manufacturing plant in King Abdullah Economic City (KAEC) that will be used to supply the local market. The new plant will initially produce 16 of the company's key drugs in five therapeutic areas: cardiovascular, pain, anti-infectives, urology, and neurology. The plant will initially employ 124 people, around half of whom are expected to be Saudi nationals. Pfizer has so far invested approximately USD 50 million in the plant, which has the potential for future expansion.